Serina Therapeutics Inc (SER)

NYSEAMERICAN: SER · IEX Real-Time Price · USD
13.46
-1.41 (-9.49%)
Mar 28, 2024, 3:45 PM EDT - Market closed

Company Description

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States.

The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.

Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology.

AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases.

The company was incorporated in 2017 and is based in Alameda, California.

Serina Therapeutics Inc
Serina Therapeutics logo
Country United States
Founded 2017
IPO Date Nov 29, 2018
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Michael West

Contact Details

Address:
1101 Marina Village Parkway, Suite 201
Alameda, California 94501
United States
Phone 510-671-8370

Stock Details

Ticker Symbol SER
Exchange NYSEAMERICAN
Fiscal Year January - December
CIK Code 0001708599
CUSIP Number 00848H108
ISIN Number US00848H1086
Employer ID 82-1436829
SIC Code 2834

Key Executives

Name Position
Eun-Jae Park CPA Chief Financial Officer
Dr. Ivan Labat Chief Information Officer
Judith Segall Secretary

Latest SEC Filings

Date Type Title
Mar 26, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 22, 2024 8-K Current Report
Mar 22, 2024 10-K Annual Report
Mar 14, 2024 8-K Current Report
Mar 7, 2024 425 Filing
Mar 7, 2024 8-K Current Report
Mar 7, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 14, 2024 8-K Current Report
Feb 14, 2024 424B3 Prospectus
Feb 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership